Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase NA 1Phase 4 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Paraproteinemias 2Immunoglobulin Light-chain Amyloidosis 2

Interventions

Carboplatin 127pembrolizumab 123Cisplatin 112Paclitaxel 102Gemcitabine 83Specimen Handling 80Magnetic Resonance Spectroscopy 80Docetaxel 69Dexamethasone 59Cyclophosphamide 59Pemetrexed 54Bevacizumab 54Doxorubicin 52durvalumab 51Radiotherapy 49Capecitabine 48Radiation 47Oxaliplatin 47Fluorouracil 47Rituximab 42Leucovorin 42Vincristine 41Lenalidomide 39Etoposide 38atezolizumab 35Nivolumab 35Letrozole 35Prednisone 31Bortezomib 31130-nm albumin-bound paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Clinical Protocols × 90 days × Clear all
NCT04512235 2026-04-07

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
281 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
125 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡